Literature DB >> 10741497

Lumbar and radial bone mineral density in children and adolescents with X-linked hypophosphatemia: evaluation with dual X-ray absorptiometry.

R M Shore1, C B Langman, A K Poznanski.   

Abstract

OBJECTIVE: To evaluate the bone mineral status of children being treated for X-linked hypophosphatemia, including potential differences between cortical bone in the radial diaphysis and combined cortical and trabecular bone in the lumbar spine. DESIGN AND PATIENTS: Forty-four bone mineral evaluations were performed in 11 children and adolescents with X-linked hypophosphatemia. Bone mineral density (BMD) of the lumbar spine and the radial diaphysis were measured by dual X-ray absorptiometry (DXA), second metacarpal cortical thickness was measured on hand radiographs, and these results were expressed as Z-scores (standard deviations from the mean).
RESULTS: For the 11 initial examinations, Z-scores (mean+/-SD) were: radial BMD, -2.73+/-1.15, lumbar BMD, +1.28+/-1.53; and cortical thickness, -2.21+/-0.95. Lumbar BMD Z-scores were significantly greater than those for radial BMD and cortical thickness. On follow-up examinations there was a mild increase in radial BMD and decrease in lumbar BMD. Although these changes were statistically significant, they were quite small and the discordance between radial and lumbar BMD was not corrected.
CONCLUSIONS: Children and adolescents who are being treated for X-linked hypophosphatemia manifest a bone mineral disorder characterized by decreased BMD in the appendicular skeleton and increased BMD in the lumbar spine. Although current therapy is successful in its anti-rachitic effects, it does not correct this bone mineral disorder and additional therapeutic trials should be considered.

Entities:  

Mesh:

Year:  2000        PMID: 10741497     DOI: 10.1007/s002560050016

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  8 in total

1.  Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets.

Authors:  G P Colares Neto; R M R Pereira; J C Alvarenga; L Takayama; M F A Funari; R M Martin
Journal:  Osteoporos Int       Date:  2017-02-13       Impact factor: 4.507

2.  Growth in X-linked hypophosphatemic rickets.

Authors:  Gema Ariceta; Craig B Langman
Journal:  Eur J Pediatr       Date:  2006-12-14       Impact factor: 3.183

Review 3.  Rickets: Part II.

Authors:  Richard M Shore; Russell W Chesney
Journal:  Pediatr Radiol       Date:  2012-11-21

4.  High bone mineral apparent density in children with X-linked hypophosphatemia.

Authors:  S S Beck-Nielsen; K Brixen; J Gram; C Mølgaard
Journal:  Osteoporos Int       Date:  2013-02-07       Impact factor: 4.507

5.  Successful Medical Therapy for Hypophosphatemic Rickets due to Mitochondrial Complex I Deficiency Induced de Toni-Debré-Fanconi Syndrome.

Authors:  Sasigarn A Bowden; Hiren P Patel; Allan Beebe; Kim L McBride
Journal:  Case Rep Pediatr       Date:  2013-12-10

Review 6.  The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment.

Authors:  Stefano Stagi; Loredana Cavalli; Salvatore Seminara; Maurizio de Martino; Maria Luisa Brandi
Journal:  Ital J Pediatr       Date:  2014-06-07       Impact factor: 2.638

7.  Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH).

Authors:  Adalbert Raimann; Sarah N Mehany; Patricia Feil; Michael Weber; Peter Pietschmann; Andrea Boni-Mikats; Radka Klepochova; Martin Krššák; Gabriele Häusler; Johannes Schneider; Janina M Patsch; Kay Raum
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-09       Impact factor: 5.555

Review 8.  Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH).

Authors:  Francis H Glorieux; Lynda F Bonewald; Nicholas C Harvey; Marjolein C H van der Meulen
Journal:  Orphanet J Rare Dis       Date:  2022-01-31       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.